Follow the people · Insider
Robert James Wills
Robert James Wills files insider transactions with the SEC as a director of Alpha Cognition (ACOG). We hold 1 disclosed purchase or sale filed since 4 March 2015, 1 of them in the last 90 days.
- Files forACOG
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure24 August 2026
Positions held
5 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 7 April 2025 — 21 August 2026Director · Alpha Cognition (ACOG)7 Form 4 lines · source: SEC Form 4
- Filed 1 October 2020 — 10 June 2026Director · Milestone Pharmaceuticals (MIST)11 Form 4 lines · source: SEC Form 4
- Filed 12 September 2019 — 20 June 2024Director · Oncternal Therapeutics (ONCT)11 Form 4 lines · source: SEC Form 4
- Filed 16 April 2015 — 22 March 2024Director · CymaBay Therapeutics (CBAY)32 Form 4 lines · source: SEC Form 4
- Filed 2 March 2015 — 26 June 2018Executive Chairman · Gtx Inc /de/ (GTXI)11 Form 4 lines · source: SEC Form 4
Everything they disclosed
72 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 10,000 shares of Alpha CognitionSEC Form 424 August 2026Common Shares · traded 21 August 2026 · filed 24 August 2026
- was granted 77,000 shares of Milestone Pharmaceuticals (a derivative holding)SEC Form 412 June 2026Stock Option (right to buy) · traded 10 June 2026 · filed 12 June 2026
- was granted 7,241 shares of Alpha CognitionSEC Form 416 January 2026Common Shares · traded 14 January 2026 · filed 16 January 2026
- was granted 8,437 shares of Alpha Cognition (a derivative holding)SEC Form 416 January 2026Common Share Options · traded 14 January 2026 · filed 16 January 2026
- was granted 8,437 shares of Alpha Cognition (a derivative holding)SEC Form 416 January 2026Common Share Options · traded 14 January 2026 · filed 16 January 2026
- was granted 7,241 shares of Alpha CognitionSEC Form 416 January 2026Common Shares · traded 14 January 2026 · filed 16 January 2026
- ▲ bought on the open market 15,000 shares of Alpha CognitionSEC Form 421 August 2025Common Stock · traded 18 August 2025 · filed 21 August 2025
- was granted 50,000 shares of Milestone Pharmaceuticals (a derivative holding)SEC Form 415 July 2025Series A Common Warrants (right to buy) · traded 11 July 2025 · filed 15 July 2025
- was granted 50,000 shares of Milestone Pharmaceuticals (a derivative holding)SEC Form 415 July 2025Series B Common Warrants (right to buy) · traded 11 July 2025 · filed 15 July 2025
- was granted 50,000 shares of Milestone PharmaceuticalsSEC Form 415 July 2025Common Shares · traded 11 July 2025 · filed 15 July 2025
- was granted 40,000 shares of Milestone Pharmaceuticals (a derivative holding)SEC Form 412 June 2025Stock Option (right to buy) · traded 10 June 2025 · filed 12 June 2025
- was granted 30,019 shares of Alpha Cognition (a derivative holding)SEC Form 49 April 2025Director Stock Option (Right to Buy) · traded 7 April 2025 · filed 9 April 2025
- was granted 40,000 shares of Milestone Pharmaceuticals (a derivative holding)SEC Form 429 August 2024Stock Option (right to buy) · traded 28 August 2024 · filed 29 August 2024
- was granted 2,200 shares of Oncternal Therapeutics (a derivative holding)SEC Form 424 June 2024Stock Options · traded 20 June 2024 · filed 24 June 2024
- ▲ bought on the open market 3,086 shares of Oncternal TherapeuticsSEC Form 410 April 2024Common Stock · traded 8 April 2024 · filed 10 April 2024
- ▲ bought on the open market 6,914 shares of Oncternal TherapeuticsSEC Form 41 April 2024Common Stock · traded 28 March 2024 · filed 1 April 2024
- returned to the issuer 18,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 422 March 2024Employee Stock Option (right to buy) · traded 22 March 2024 · filed 22 March 2024
- returned to the issuer 25,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 422 March 2024Employee Stock Option (right to buy) · traded 22 March 2024 · filed 22 March 2024
- returned to the issuer 9,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 422 March 2024Employee Stock Option (right to buy) · traded 22 March 2024 · filed 22 March 2024
- returned to the issuer 27,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 422 March 2024Employee Stock Option (right to buy) · traded 22 March 2024 · filed 22 March 2024
- returned to the issuer 15,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 422 March 2024Employee Stock Option (right to buy) · traded 22 March 2024 · filed 22 March 2024
- returned to the issuer 7,500 shares of CymaBay Therapeutics (a derivative holding)SEC Form 422 March 2024Employee Stock Option (right to buy) · traded 22 March 2024 · filed 22 March 2024
- returned to the issuer 16,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 422 March 2024Employee Stock Option (right to buy) · traded 22 March 2024 · filed 22 March 2024
- returned to the issuer 27,705 shares of CymaBay Therapeutics (a derivative holding)SEC Form 422 March 2024Employee Stock Option (right to buy) · traded 22 March 2024 · filed 22 March 2024
- returned to the issuer 49,245 shares of CymaBay Therapeutics (a derivative holding)SEC Form 422 March 2024Employee Stock Option (right to buy) · traded 22 March 2024 · filed 22 March 2024
- returned to the issuer 32,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 422 March 2024Employee Stock Option (right to buy) · traded 22 March 2024 · filed 22 March 2024
- returned to the issuer 67,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 422 March 2024Employee Stock Option (right to buy) · traded 22 March 2024 · filed 22 March 2024
- returned to the issuer 25,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 422 March 2024Employee Stock Option (right to buy) · traded 22 March 2024 · filed 22 March 2024
- returned to the issuer 14,010 shares of CymaBay Therapeutics (a derivative holding)SEC Form 422 March 2024Employee Stock Option (right to buy) · traded 22 March 2024 · filed 22 March 2024
- returned to the issuer 30,000 shares of CymaBay TherapeuticsSEC Form 422 March 2024Common Stock · traded 22 March 2024 · filed 22 March 2024
- ▼ sold on the open market 980 shares of Oncternal TherapeuticsSEC Form 427 February 2024Common Stock · traded 23 February 2024 · filed 27 February 2024
- was granted 14,010 shares of CymaBay Therapeutics (a derivative holding)SEC Form 426 January 2024Stock Option (right to buy) · traded 24 January 2024 · filed 26 January 2024
- was granted 25,000 shares of Oncternal Therapeutics (a derivative holding)SEC Form 430 June 2023Stock Options · traded 28 June 2023 · filed 30 June 2023
- was granted 30,000 shares of Milestone Pharmaceuticals (a derivative holding)SEC Form 49 June 2023Stock Option (right to buy) · traded 7 June 2023 · filed 9 June 2023
- was granted 25,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 427 January 2023Stock Option (right to buy) · traded 25 January 2023 · filed 27 January 2023
- ▲ bought on the open market 15,000 shares of Milestone PharmaceuticalsSEC Form 421 October 2022Common Shares · traded 19 October 2022 · filed 21 October 2022
- was granted 30,000 shares of Milestone Pharmaceuticals (a derivative holding)SEC Form 411 August 2022Stock Option (right to buy) · traded 5 July 2022 · filed 11 August 2022
- was granted 25,000 shares of Oncternal Therapeutics (a derivative holding)SEC Form 417 June 2022Stock Options · traded 16 June 2022 · filed 17 June 2022
- was granted 67,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 427 January 2022Stock Option (right to buy) · traded 25 January 2022 · filed 27 January 2022
- was granted 30,000 shares of Milestone Pharmaceuticals (a derivative holding)SEC Form 429 July 2021Stock Option (right to buy) · traded 14 June 2021 · filed 29 July 2021
- was granted 25,000 shares of Oncternal Therapeutics (a derivative holding)SEC Form 427 May 2021Stock Options · traded 25 May 2021 · filed 27 May 2021
- was granted 32,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 428 January 2021Stock Option (right to buy) · traded 26 January 2021 · filed 28 January 2021
- was granted 30,000 shares of Milestone Pharmaceuticals (a derivative holding)SEC Form 45 October 2020Stock Option (right to buy) · traded 1 October 2020 · filed 5 October 2020
- was granted 15,000 shares of Oncternal Therapeutics (a derivative holding)SEC Form 431 July 2020Stock Option · traded 11 June 2020 · filed 31 July 2020
- was granted 30,000 shares of Oncternal Therapeutics (a derivative holding)SEC Form 431 July 2020Stock Options · traded 12 September 2019 · filed 31 July 2020
- was granted 15,000 shares of Oncternal Therapeutics (a derivative holding)SEC Form 412 June 2020Stock Options · traded 11 June 2020 · filed 12 June 2020
- was granted 49,245 shares of CymaBay Therapeutics (a derivative holding)SEC Form 419 May 2020Stock Option (Right to Buy) · traded 15 May 2020 · filed 19 May 2020
- was granted 30,000 shares of Oncternal Therapeutics (a derivative holding)SEC Form 416 September 2019Stock Option · traded 12 September 2019 · filed 16 September 2019
- was granted 27,705 shares of CymaBay Therapeutics (a derivative holding)SEC Form 431 January 2019Stock Option (right to buy) · traded 29 January 2019 · filed 31 January 2019
- ▲ bought on the open market 5,000 shares of Gtx Inc /de/SEC Form 426 June 2018Common Stock · traded 26 June 2018 · filed 26 June 2018
- was granted 16,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 426 January 2018Stock Option (right to buy) · traded 24 January 2018 · filed 26 January 2018
- was granted 65,000 shares of Gtx Inc /de/ (a derivative holding)SEC Form 43 January 2018Employee Stock Option (Right to Buy) · traded 1 January 2018 · filed 3 January 2018
- was granted 7,500 shares of CymaBay Therapeutics (a derivative holding)SEC Form 426 September 2017Stock Option (right to buy) · traded 22 September 2017 · filed 26 September 2017
- ▲ bought on the open market 200 shares of CymaBay TherapeuticsSEC Form 42 August 2017Common Stock · traded 1 August 2017 · filed 2 August 2017
- ▲ bought on the open market 300 shares of CymaBay TherapeuticsSEC Form 42 August 2017Common Stock · traded 1 August 2017 · filed 2 August 2017
- ▲ bought on the open market 1,000 shares of CymaBay TherapeuticsSEC Form 42 August 2017Common Stock · traded 1 August 2017 · filed 2 August 2017
- ▲ bought on the open market 3,500 shares of CymaBay TherapeuticsSEC Form 42 August 2017Common Stock · traded 1 August 2017 · filed 2 August 2017
- was granted 15,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 430 June 2017Stock Option (right to buy) · traded 28 June 2017 · filed 30 June 2017
- was granted 27,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 41 May 2017Stock Option (right to buy) · traded 27 April 2017 · filed 1 May 2017
- was granted 95,000 shares of Gtx Inc /de/ (a derivative holding)SEC Form 42 March 2017Employee Stock Option (Right to Buy) · traded 28 February 2017 · filed 2 March 2017
- was granted 123,456 shares of Gtx Inc /de/SEC Form 417 October 2016Common Stock · traded 14 October 2016 · filed 17 October 2016
- ▲ bought on the open market 25,000 shares of CymaBay TherapeuticsSEC Form 49 September 2016Common Stock · traded 6 September 2016 · filed 9 September 2016
- was granted 9,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 430 June 2016Stock Option (right to buy) · traded 28 June 2016 · filed 30 June 2016
- ▲ bought on the open market 100,000 shares of Gtx Inc /de/SEC Form 420 June 2016Common Stock · traded 16 June 2016 · filed 20 June 2016
- was granted 400,000 shares of Gtx Inc /de/ (a derivative holding)SEC Form 44 January 2016Employee Stock Option (Right to Buy) · traded 1 January 2016 · filed 4 January 2016
- was granted 25,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 48 October 2015Stock Option (right to buy) · traded 6 October 2015 · filed 8 October 2015
- ▲ bought on the open market 9,700 shares of Gtx Inc /de/SEC Form 414 May 2015Common Stock · traded 13 May 2015 · filed 14 May 2015
- ▲ bought on the open market 36,440 shares of Gtx Inc /de/SEC Form 414 May 2015Common Stock · traded 14 May 2015 · filed 14 May 2015
- ▲ bought on the open market 3,860 shares of Gtx Inc /de/SEC Form 413 May 2015Common Stock · traded 11 May 2015 · filed 13 May 2015
- ▲ bought on the open market 50,000 shares of Gtx Inc /de/SEC Form 411 May 2015Common Stock · traded 8 May 2015 · filed 11 May 2015
- was granted 18,000 shares of CymaBay Therapeutics (a derivative holding)SEC Form 424 April 2015Stock Option (right to buy) · traded 16 April 2015 · filed 24 April 2015
- was granted 1,000,000 shares of Gtx Inc /de/SEC Form 44 March 2015Common Stock · traded 2 March 2015 · filed 4 March 2015
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.